Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Obesity and Overweight

In brief

A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

Key facts

Study ID

NCT06732245

Run by

Biomed Industries, Inc.

People needed

224

Starts

2026-08-15

Expected to finish

2027-12-15

Last updated by the study team

2026-03-27

Who can join

Age: 19 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A written informed consent must be obtained before any study-related assessments are performed.
• Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:
• Two negative pregnancy tests (at screening and at randomization, prior to dosing)
• Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral.
• Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)
• Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg
• Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
• Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration

You may not qualify if…

• • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®)
• Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations
• Treatment with any medication for the indication of obesity within the past 30 days before screening
• Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.
• Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose
• Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol

Where it is running

• Biomed Research Unit #90067-102 — Los Angeles, California, United States
• Biomed Research Unit # 92121-103 — San Diego, California, United States
• Biomed Research Unit # 94104-101 — San Francisco, California, United States
• Biomed Research Unit # 33012-104 — Hialeah, Florida, United States
• Biomed Research Unit # 32256-105 — Jacksonville, Florida, United States
• Biomed Research Unit # 33461-106 — Lake Worth, Florida, United States
• Biomed Research Unit # 10021-107 — New York, New York, United States
• Biomed Research Unit # 77479-108 — Sugar Land, Texas, United States
• Biomed Research Unit-NSW-2100-109 — Brookvale, New South Wales, Australia
• Biomed Research Unit-NSW-2065-110 — Saint Leonards,, New South Wales, Australia
• , Australia, 4101 Biomed Research Unit-NSW-4101-111 — South Brisbane, Queensland, Australia
• Biomed Research Unit-VIC-3124-112 — Camberwell, Victoria, Australia
• , Victoria, Australia, 3084 Biomed Research Unit-VIC-3084-113 — Heidelberg West, Victoria, Australia
• Biomed Research Unit-NZ-2025-115 — Papatoetoe, Auckland, New Zealand
• Biomed Research Unit-NZ- 6242-117 — Newtown, Wellington Region, New Zealand
• Biomed Research Unit-NZ-1010-114 — Auckland, New Zealand
• Hamilton, New Zealand, 3200 Biomed Research Unit-NZ-3200-116 — Hamilton, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.